(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number
WO 2004/022569 A1

(51) International Patent Classification[7]: C07F 9/117, C07C 59/13, 59/68, A61K 31/683, 31/185, A61P 35/00

(21) International Application Number:
PCT/US2003/027607

(22) International Filing Date:
3 September 2003 (03.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/407,239 3 September 2002 (03.09.2002) US

(71) Applicants *(for all designated States except US)*: **GEORGETOWN UNIVERSITY** [US/US]; 37th & O Streets, N.W., Washington, DC 20057 (US). **THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as representedby THE SECRETARY, DEPARTMENT OF HEALT H ANDHUMANSERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KOZIKOWSKI, Alan, P.** [US/US]; 1600 Oak St., N, Apt 1022, Arlington, VA 22209 (US). **DENNIS, Phillip** [US/US]; 2327 Daniels, Rd., Ellicott City, MD 21043 (US). **SUN, Haiying** [CN/US]; 1515 Jones Dr., Apt 14, Ann Arbor, MI 48105 (US). **BROGNARD, John** [US/US]; 821 Skysail Ave., Carlsbad, CA 92009 (US).

(74) Agents: **PILLAI, Xavier** et al.; Leydig, Voit & Mayer, LTD., Two Prudential Plaza, Suite 4900, 180 North Stetson, Chicago, IL 60601-6780 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(48) Date of publication of this corrected version:
10 June 2004

(15) Information about Correction:
see PCT Gazette No. 24/2004 of 10 June 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AKT INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF



(I)

(57) Abstract: Disclosed are inhibitors of the serine/threonine kinase Akt, pharmaceutical compositions comprising such inhibitors, and a method of preventing or treating a disease or condition in an animal by the use of such inhibitors. The Akt inhibitors have the formula (I) wherein X and Y are independently selected from the group consisting of O, CF_2, CH_2, and CHF; wherein A is independently selected from the group consisting of P(O)OH, CH_2000H, and $CH(COOH)_2$; R_2 is selected from the group consisting of H, OH, isosteres of OH, C_1-C_{25} alkyloxy, C_6-C_{10} aryloxy, C_3-C_8 cycloalkyloxy, C_3-C_8 cycloalkyl C_1-C_6 alkoxy, C_2-C_{22} alkenyloxy, C_3-C_8 cycloalkenyloxy, C_7-C_{32} aralkyloxy, C_7-C_{32} alkylaryloxy, C_9-C_{32} aralkenyloxy, and C_9-C_{32} alkenylaryloxy; R_3-R_6 are independently selected from the group consisting of H, OH, isosteres of OH; and R_1 and R_7 are independently selected from the group consisting of C_1-C_{25} alkyl, C_6-C_{10} aryl, C_3-C_8 cycloalkyl, C_2-C_{22} alkenyl, C_3-C_8 cycloalkenyl, C_7-C_{32} aralkyl, C_7-C_{32} alkylaryl, C_9-C_{32} aralkenyl, and C_9-C_{32} alkenylaryl; with the provisos that (i) when X is O, Y is O or CH_2, and R_3 is H, at least one of R_2 and R_4-R_6 is not OH; (ii) when A is CH_2C00H or $CH(COOH)_2$, X and Y cannot be simultaneously O; and (iii) all of R_2-R_6 are not simultaneously H. The inhibitors can be in the form of a salt also.

WO 2004/022569 A1